AI Engines For more Details: Perplexity Kagi Labs You
Motion Sickness: Cinnarizine is effective in preventing and relieving symptoms of motion sickness, including nausea, vomiting, dizziness, and vertigo, commonly experienced during travel by car, boat, or airplane. It works by blocking histamine H1 receptors in the vestibular system and the vomiting center of the brain, thereby reducing the sensitivity of the inner ear to motion stimuli and decreasing the likelihood of motion sickness symptoms.
Vertigo: Cinnarizine is also used to treat vertigo, a sensation of spinning or dizziness often associated with inner ear disorders such as benign paroxysmal positional vertigo (BPPV), vestibular neuritis, and Meniere's disease. By exerting its antihistamine and calcium channel blocking effects, cinnarizine helps alleviate vertigo symptoms and improve balance and stability in affected individuals.
Peripheral Vestibular Disorders: Cinnarizine may be prescribed for individuals with peripheral vestibular disorders characterized by disturbances in balance and spatial orientation, such as labyrinthitis, vestibular neuronitis, and vestibular migraine. It can help reduce vertigo attacks and associated symptoms, allowing patients to better cope with their condition and maintain daily activities.
Inner Ear Disorders: Cinnarizine is sometimes used off-label in the treatment of various inner ear disorders, including tinnitus (ringing in the ears) and hearing loss associated with vestibular dysfunction. Although its efficacy in these conditions is less well-established, cinnarizine may provide symptomatic relief by modulating blood flow and reducing the hyperexcitability of the vestibular system.
Ménière's Disease: Cinnarizine may be prescribed as part of the management plan for individuals with Ménière's disease, a chronic inner ear disorder characterized by recurrent episodes of vertigo, sensorineural hearing loss, tinnitus, and a sensation of fullness or pressure in the affected ear. Cinnarizine can help alleviate vertigo attacks and associated symptoms, although its long-term efficacy in preventing disease progression is uncertain.
Side Effects: Common side effects of cinnarizine may include drowsiness, dry mouth, blurred vision, constipation, and gastrointestinal disturbances. These side effects are usually mild and transient, and they may diminish with continued use or dose adjustment. Cinnarizine may cause drowsiness or impair alertness, so individuals should avoid activities that require mental alertness or coordination, such as driving or operating heavy machinery, until they know how the medication affects them.
Contraindications: Cinnarizine is contraindicated in individuals with a known hypersensitivity to the medication or any of its components, as well as those with Parkinson's disease, hypotension, severe heart failure, or severe hepatic impairment. It should be used with caution in elderly patients and those with glaucoma, urinary retention, or prostatic hypertrophy.
Rank | Probiotic | Impact |
---|---|---|
genus | Bifidobacterium | Reduces |
species | Bacteroides uniformis | Reduces |
species | Bifidobacterium adolescentis | Reduces |
species | Bifidobacterium longum | Reduces |
species | Escherichia coli | Reduces |
species | Lacticaseibacillus paracasei | Reduces |
species | Parabacteroides distasonis | Reduces |
subspecies | Bifidobacterium longum subsp. infantis | Reduces |
subspecies | Bifidobacterium longum subsp. longum | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
π Direct Citations | πͺπΆ Indirect Citations | Taxonomy | Rank | Effect |
---|---|---|---|---|
0 | 1 | Escherichia | genus | Decreases |
0 | 1 | Dorea | genus | Decreases |
0 | 1 | Roseburia | genus | Decreases |
0 | 1 | Parabacteroides | genus | Decreases |
0 | 1 | Ruminococcus | genus | Decreases |
0 | 1 | Agathobacter | genus | Decreases |
0 | 1 | Bacteroides | genus | Decreases |
0 | 1 | Bifidobacterium | genus | Decreases |
0 | 1 | Bilophila | genus | Decreases |
0 | 1 | Clostridioides | genus | Decreases |
0 | 1 | Collinsella | genus | Decreases |
0 | 1 | Coprococcus | genus | Decreases |
0 | 1 | Eggerthella | genus | Decreases |
0 | 1 | Lachnospira | genus | Decreases |
0 | 1 | Lacrimispora | genus | Decreases |
0 | 1 | Mediterraneibacter | genus | Decreases |
0 | 1 | Odoribacter | genus | Decreases |
0 | 1 | Phocaeicola | genus | Decreases |
0 | 1 | Streptococcus | genus | Decreases |
0 | 1 | Veillonella | genus | Decreases |
0 | 1 | Clostridium | genus | Decreases |
0 | 1 | Segatella | genus | Decreases |
0 | 1 | Enterocloster | genus | Decreases |
0 | 1 | Blautia | genus | Decreases |
0 | 1 | Thomasclavelia | genus | Decreases |
0 | 1 | Lacticaseibacillus | genus | Decreases |
0 | 1 | Escherichia coli O25:H16 | no rank | Decreases |
0 | 1 | Clostridium perfringens A | no rank | Decreases |
0 | 1 | Clostridium perfringens C | no rank | Decreases |
0 | 1 | Clostridium perfringens CPE | no rank | Decreases |
0 | 1 | Escherichia coli O145:H34 | no rank | Decreases |
0 | 1 | Escherichia coli O16:H48 | no rank | Decreases |
0 | 1 | Clostridium perfringens D | no rank | Decreases |
0 | 1 | Escherichia coli O141:H4 | no rank | Decreases |
0 | 1 | Clostridium perfringens B | no rank | Decreases |
0 | 1 | Escherichia coli O139:H1 | no rank | Decreases |
0 | 1 | Clostridium perfringens E | no rank | Decreases |
0 | 1 | Escherichia coli O80:H26 | no rank | Decreases |
0 | 1 | Escherichia coli O158:H23 | no rank | Decreases |
0 | 1 | Escherichia coli O84:H7 | no rank | Decreases |
0 | 1 | Escherichia coli O2:K1:H4 | no rank | Decreases |
0 | 1 | Escherichia coli O2:K1:H7 | no rank | Decreases |
0 | 1 | Escherichia coli O78:H51 | no rank | Decreases |
0 | 1 | Escherichia coli O18ac:H14 | no rank | Decreases |
0 | 1 | Escherichia coli O85:H1 | no rank | Decreases |
0 | 1 | Escherichia coli O7:H15 | no rank | Decreases |
0 | 1 | Escherichia coli O68:H12 | no rank | Decreases |
0 | 1 | Escherichia coli O55:H7 | no rank | Decreases |
0 | 1 | Escherichia coli O1:K1:H7 | no rank | Decreases |
0 | 1 | Escherichia coli O15:H12 | no rank | Decreases |
0 | 1 | Escherichia coli O170:H18 | no rank | Decreases |
0 | 1 | Escherichia coli O155:H21 | no rank | Decreases |
0 | 1 | Escherichia coli O19:H7 | no rank | Decreases |
0 | 1 | Escherichia coli O2:K1:H5 | no rank | Decreases |
0 | 1 | Escherichia coli O20:H12 | no rank | Decreases |
0 | 1 | Escherichia coli O111 | serogroup | Decreases |
0 | 1 | Escherichia coli O121 | serogroup | Decreases |
0 | 1 | Escherichia coli O155 | serogroup | Decreases |
0 | 1 | Escherichia coli O177 | serogroup | Decreases |
0 | 1 | Escherichia coli O26 | serogroup | Decreases |
0 | 1 | Escherichia coli O3 | serogroup | Decreases |
0 | 1 | Escherichia coli O5 | serogroup | Decreases |
0 | 1 | Escherichia coli O86 | serogroup | Decreases |
0 | 1 | Escherichia coli O91 | serogroup | Decreases |
0 | 1 | Escherichia coli O103 | serogroup | Decreases |
0 | 1 | Escherichia coli O78 | serogroup | Decreases |
0 | 1 | Escherichia coli O43 | serogroup | Decreases |
0 | 1 | Escherichia coli O119 | serogroup | Decreases |
0 | 1 | Escherichia coli O157 | serogroup | Decreases |
0 | 1 | Escherichia coli O145 | serogroup | Decreases |
0 | 1 | Escherichia coli O1:HNT | serotype | Decreases |
0 | 1 | Escherichia coli O10:K5(L):H4 | serotype | Decreases |
0 | 1 | Escherichia coli O103:H11 | serotype | Decreases |
0 | 1 | Escherichia coli O103:H25 | serotype | Decreases |
0 | 1 | Escherichia coli O104:H21 | serotype | Decreases |
0 | 1 | Escherichia coli O111:H11 | serotype | Decreases |
0 | 1 | Escherichia coli O111:H8 | serotype | Decreases |
0 | 1 | Escherichia coli O112ac:H19 | serotype | Decreases |
0 | 1 | Escherichia coli O114:H49 | serotype | Decreases |
0 | 1 | Escherichia coli O118:H16 | serotype | Decreases |
0 | 1 | Escherichia coli O121:H7 | serotype | Decreases |
0 | 1 | Escherichia coli O123:H11 | serotype | Decreases |
0 | 1 | Escherichia coli O127:H27 | serotype | Decreases |
0 | 1 | Escherichia coli O127:H6 | serotype | Decreases |
0 | 1 | Escherichia coli O128:H2 | serotype | Decreases |
0 | 1 | Escherichia coli O128ac:H12 | serotype | Decreases |
0 | 1 | Escherichia coli O145:H25 | serotype | Decreases |
0 | 1 | Escherichia coli O145:NM | serotype | Decreases |
0 | 1 | Escherichia coli O146:H21 | serotype | Decreases |
0 | 1 | Escherichia coli O153:H2 | serotype | Decreases |
0 | 1 | Escherichia coli O156:H25 | serotype | Decreases |
0 | 1 | Escherichia coli O157:H43 | serotype | Decreases |
0 | 1 | Escherichia coli O157:NM | serotype | Decreases |
0 | 1 | Escherichia coli O165:H25 | serotype | Decreases |
0 | 1 | Escherichia coli O174:H2 | serotype | Decreases |
0 | 1 | Escherichia coli O174:H21 | serotype | Decreases |
0 | 1 | Escherichia coli O174:H8 | serotype | Decreases |
0 | 1 | Escherichia coli O176:H45 | serotype | Decreases |
0 | 1 | Escherichia coli O177:NM | serotype | Decreases |
0 | 1 | Escherichia coli O26:H1 | serotype | Decreases |
0 | 1 | Escherichia coli O28ac:NM | serotype | Decreases |
0 | 1 | Escherichia coli O29:H4 | serotype | Decreases |
0 | 1 | Escherichia coli O32:H37 | serotype | Decreases |
0 | 1 | Escherichia coli O6:H16:CFA/II | serotype | Decreases |
0 | 1 | Escherichia coli O69:H11 | serotype | Decreases |
0 | 1 | Escherichia coli O78:H12 | serotype | Decreases |
0 | 1 | Escherichia coli O79:H7 | serotype | Decreases |
0 | 1 | Escherichia coli O81:NM | serotype | Decreases |
0 | 1 | Escherichia coli O86:H34 | serotype | Decreases |
0 | 1 | Escherichia coli O91:H14 | serotype | Decreases |
0 | 1 | Escherichia coli O91:NM | serotype | Decreases |
0 | 1 | Escherichia coli ONT:H33 | serotype | Decreases |
0 | 1 | Escherichia coli O100:H21 | serotype | Decreases |
0 | 1 | Escherichia coli O121:H19 | serotype | Decreases |
0 | 1 | Escherichia coli O157:H7 | serotype | Decreases |
0 | 1 | Escherichia coli O16:H6 | serotype | Decreases |
0 | 1 | Escherichia coli O89m:H9 | serotype | Decreases |
0 | 1 | Escherichia coli O111:H- | serotype | Decreases |
0 | 1 | Escherichia coli O113:H21 | serotype | Decreases |
0 | 1 | Escherichia coli H20 | serotype | Decreases |
0 | 1 | Escherichia coli O150:H6 | serotype | Decreases |
0 | 1 | Escherichia coli O111:NM | serotype | Decreases |
0 | 1 | Escherichia coli O112ab:H8 | serotype | Decreases |
0 | 1 | Escherichia coli O99:H6 | serotype | Decreases |
0 | 1 | Escherichia coli O26:H11 | serotype | Decreases |
0 | 1 | Escherichia coli O145:H28 | serotype | Decreases |
0 | 1 | Escherichia coli O126:H45 | serotype | Decreases |
0 | 1 | Escherichia coli O2:H6 | serotype | Decreases |
0 | 1 | Escherichia coli O7:H4 | serotype | Decreases |
0 | 1 | Escherichia coli O1:H42 | serotype | Decreases |
0 | 1 | Escherichia coli O25:NM | serotype | Decreases |
0 | 1 | Escherichia coli O25:H1 | serotype | Decreases |
0 | 1 | Escherichia coli O7:K1 | serotype | Decreases |
0 | 1 | Escherichia coli O125ac:K+:H10 | serotype | Decreases |
0 | 1 | Escherichia coli O6:K2:H1 | serotype | Decreases |
0 | 1 | Escherichia coli O152:H23 | serotype | Decreases |
0 | 1 | Escherichia coli O15:H18 | serotype | Decreases |
0 | 1 | Escherichia coli O39:NM | serotype | Decreases |
0 | 1 | Escherichia coli O44:H18 | serotype | Decreases |
0 | 1 | Escherichia coli O2:K2:H1 | serotype | Decreases |
0 | 1 | Escherichia coli O8:H8 | serotype | Decreases |
0 | 1 | Escherichia coli O89m:H10 | serotype | Decreases |
0 | 1 | Escherichia coli O10:H32 | serotype | Decreases |
0 | 1 | Escherichia coli O6:H16 | serotype | Decreases |
0 | 1 | Escherichia coli O157:H- | serotype | Decreases |
0 | 1 | Escherichia coli O45:H2 | serotype | Decreases |
0 | 1 | Escherichia coli O103:H2 | serotype | Decreases |
0 | 1 | Escherichia coli O167:H26 | serotype | Decreases |
0 | 1 | Escherichia coli O104:H4 | serotype | Decreases |
0 | 1 | Escherichia coli O83:H1 | serotype | Decreases |
0 | 1 | Escherichia coli O9:H10 | serotype | Decreases |
0 | 1 | Escherichia coli O78:H4 | serotype | Decreases |
0 | 1 | Escherichia coli O139:H28 | serotype | Decreases |
1 | 0 | Clostridium perfringens | species | Decreases |
1 | 0 | Lacticaseibacillus paracasei | species | Decreases |
1 | 0 | [Ruminococcus] torques | species | Decreases |
1 | 0 | Agathobacter rectalis | species | Decreases |
1 | 0 | Bacteroides ovatus | species | Decreases |
1 | 0 | Bacteroides thetaiotaomicron | species | Decreases |
1 | 0 | Bacteroides uniformis | species | Decreases |
1 | 0 | Bifidobacterium adolescentis | species | Decreases |
1 | 0 | Bifidobacterium longum | species | Decreases |
1 | 0 | Blautia obeum | species | Decreases |
1 | 0 | Clostridioides difficile | species | Decreases |
1 | 0 | Collinsella aerofaciens | species | Decreases |
1 | 0 | Coprococcus comes | species | Decreases |
1 | 0 | Dorea formicigenerans | species | Decreases |
1 | 0 | Eggerthella lenta | species | Decreases |
1 | 0 | Enterocloster bolteae | species | Decreases |
1 | 0 | Escherichia coli | species | Decreases |
1 | 0 | Lachnospira eligens | species | Decreases |
1 | 0 | Mediterraneibacter gnavus | species | Decreases |
1 | 0 | Phocaeicola vulgatus | species | Decreases |
1 | 0 | Roseburia intestinalis | species | Decreases |
1 | 0 | Segatella copri | species | Decreases |
1 | 0 | Streptococcus parasanguinis | species | Decreases |
1 | 0 | Thomasclavelia ramosa | species | Decreases |
1 | 0 | Odoribacter splanchnicus | species | Decreases |
1 | 0 | Lacrimispora saccharolytica | species | Decreases |
1 | 0 | Veillonella parvula | species | Decreases |
1 | 0 | Ruminococcus bromii | species | Decreases |
1 | 0 | Streptococcus salivarius | species | Decreases |
1 | 0 | Parabacteroides merdae | species | Decreases |
1 | 0 | Bacteroides caccae | species | Decreases |
1 | 0 | Bacteroides fragilis | species | Decreases |
1 | 0 | Bilophila wadsworthia | species | Decreases |
1 | 0 | Bacteroides xylanisolvens | species | Decreases |
1 | 0 | Parabacteroides distasonis | species | Decreases |
0 | 1 | Bifidobacterium longum subsp. longum | subspecies | Decreases |
0 | 1 | Bifidobacterium longum subsp. infantis | subspecies | Decreases |
0 | 1 | Bifidobacterium longum subsp. suis | subspecies | Decreases |
0 | 1 | Lacticaseibacillus paracasei subsp. paracasei | subspecies | Decreases |
0 | 1 | Lacticaseibacillus paracasei subsp. tolerans | subspecies | Decreases |
0 | 1 | Bifidobacterium longum subsp. suillum | subspecies | Decreases |
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
---|---|---|---|
Abdominal Aortic Aneurysm | 0.9 | 0.9 | |
Acne | 0.6 | 0.9 | -0.5 |
ADHD | 5.1 | 0.9 | 4.67 |
Age-Related Macular Degeneration and Glaucoma | 1.1 | 0.4 | 1.75 |
Allergic Rhinitis (Hay Fever) | 3.4 | 3 | 0.13 |
Allergies | 7 | 3 | 1.33 |
Allergy to milk products | 2 | 1.6 | 0.25 |
Alopecia (Hair Loss) | 1 | 1 | |
Alzheimer's disease | 5.4 | 6.5 | -0.2 |
Amyotrophic lateral sclerosis (ALS) Motor Neuron | 2.9 | 0.9 | 2.22 |
Ankylosing spondylitis | 4.3 | 1.5 | 1.87 |
Anorexia Nervosa | 1.6 | 2.9 | -0.81 |
Antiphospholipid syndrome (APS) | 2.1 | 0.3 | 6 |
Asthma | 5.7 | 2.3 | 1.48 |
Atherosclerosis | 2 | 2.5 | -0.25 |
Atrial fibrillation | 3.7 | 3.1 | 0.19 |
Autism | 10.8 | 9.6 | 0.13 |
Autoimmune Disease | 1.2 | 1 | 0.2 |
Barrett esophagus cancer | 0.3 | 0.3 | 0 |
benign prostatic hyperplasia | 0.6 | 0.3 | 1 |
Biofilm | 2.4 | 2.4 | |
Bipolar Disorder | 2.4 | 1.7 | 0.41 |
Brain Trauma | 0.9 | 1.4 | -0.56 |
Breast Cancer | 1.2 | 0.3 | 3 |
Cancer (General) | 0.6 | 3.1 | -4.17 |
Carcinoma | 4.1 | 2.6 | 0.58 |
Celiac Disease | 3.2 | 3.8 | -0.19 |
Cerebral Palsy | 1.4 | 1.3 | 0.08 |
Chronic Fatigue Syndrome | 6.2 | 6.4 | -0.03 |
Chronic Kidney Disease | 4.8 | 2.9 | 0.66 |
Chronic Lyme | 0.6 | 0.8 | -0.33 |
Chronic Obstructive Pulmonary Disease (COPD) | 2.5 | 1.7 | 0.47 |
Chronic Urticaria (Hives) | 2 | 0.8 | 1.5 |
Coagulation / Micro clot triggering bacteria | 1.9 | 1.3 | 0.46 |
Cognitive Function | 3.6 | 1.6 | 1.25 |
Colorectal Cancer | 7.9 | 2.8 | 1.82 |
Constipation | 2.1 | 1.3 | 0.62 |
Coronary artery disease | 3 | 2.7 | 0.11 |
COVID-19 | 11 | 13 | -0.18 |
Crohn's Disease | 8.1 | 5.2 | 0.56 |
Cushing's Syndrome (hypercortisolism) | 0.9 | -0.9 | |
cystic fibrosis | 1.2 | 1.9 | -0.58 |
d-lactic acidosis (one form of brain fog) | 0.6 | 0.6 | |
deep vein thrombosis | 2.7 | 1.4 | 0.93 |
Denture Wearers Oral Shifts | 1.2 | 1.2 | |
Depression | 11.4 | 9.1 | 0.25 |
Dermatomyositis | 0.3 | 0.3 | 0 |
Eczema | 2 | 2.1 | -0.05 |
Endometriosis | 3.5 | 2.6 | 0.35 |
Eosinophilic Esophagitis | 0.6 | -0.6 | |
Epilepsy | 3.4 | 1.6 | 1.13 |
erectile dysfunction | 2.2 | 0.3 | 6.33 |
Fibromyalgia | 3.4 | 2.6 | 0.31 |
Functional constipation / chronic idiopathic constipation | 6.5 | 4.2 | 0.55 |
gallstone disease (gsd) | 4 | 0.8 | 4 |
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 1.1 | 1.2 | -0.09 |
Generalized anxiety disorder | 3.1 | 2.5 | 0.24 |
giant cell arteritis | 0.2 | -0.2 | |
Glioblastoma | 0.3 | -0.3 | |
Gout | 1.2 | 0.8 | 0.5 |
Graves' disease | 1.9 | 3.3 | -0.74 |
Gulf War Syndrome | 0.9 | 1.1 | -0.22 |
Halitosis | 0.9 | 0.3 | 2 |
Hashimoto's thyroiditis | 3.3 | 1.8 | 0.83 |
Heart Failure | 4.8 | 1.9 | 1.53 |
hemorrhagic stroke | 1 | 1 | |
Hidradenitis Suppurativa | 1.2 | 0.3 | 3 |
High Histamine/low DAO | 2 | 0.6 | 2.33 |
hypercholesterolemia (High Cholesterol) | 1.1 | 1.1 | |
hyperglycemia | 2.1 | 1.1 | 0.91 |
Hyperlipidemia (High Blood Fats) | 0.9 | 0.3 | 2 |
hypersomnia | 0.7 | -0.7 | |
hypertension (High Blood Pressure | 4.5 | 5.4 | -0.2 |
Hypothyroidism | 1 | -1 | |
Hypoxia | 3.6 | 0.9 | 3 |
IgA nephropathy (IgAN) | 1.6 | 5.4 | -2.38 |
Inflammatory Bowel Disease | 9.1 | 9.2 | -0.01 |
Insomnia | 2.3 | 2.4 | -0.04 |
Intelligence | 2 | 0.6 | 2.33 |
Intracranial aneurysms | 1.2 | 0.9 | 0.33 |
Irritable Bowel Syndrome | 7.5 | 5.3 | 0.42 |
ischemic stroke | 3.2 | 1.7 | 0.88 |
Liver Cirrhosis | 7.2 | 4 | 0.8 |
Long COVID | 7.6 | 8.4 | -0.11 |
Low bone mineral density | 1.1 | -1.1 | |
Lung Cancer | 1.2 | 1 | 0.2 |
Lymphoma | 0.6 | 0.6 | |
Mast Cell Issues / mastitis | 0.9 | 0.9 | 0 |
ME/CFS with IBS | 1.1 | 2.4 | -1.18 |
ME/CFS without IBS | 2 | 1.8 | 0.11 |
membranous nephropathy | 0.3 | 0.3 | |
Menopause | 2.1 | 0.5 | 3.2 |
Metabolic Syndrome | 7.6 | 7.2 | 0.06 |
Mood Disorders | 10.7 | 8.3 | 0.29 |
multiple chemical sensitivity [MCS] | 1 | 0.1 | 9 |
Multiple Sclerosis | 7.5 | 6.1 | 0.23 |
Multiple system atrophy (MSA) | 0.6 | 0.7 | -0.17 |
myasthenia gravis | 0.9 | 0.7 | 0.29 |
neuropathic pain | 0.3 | 2.5 | -7.33 |
Neuropathy (all types) | 0.7 | 2.7 | -2.86 |
neuropsychiatric disorders (PANDAS, PANS) | 1.2 | 1.2 | |
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 6.1 | 4.8 | 0.27 |
NonCeliac Gluten Sensitivity | 1.3 | 0.6 | 1.17 |
Obesity | 9.9 | 7.5 | 0.32 |
obsessive-compulsive disorder | 6.5 | 4.2 | 0.55 |
Osteoarthritis | 3.3 | 1.2 | 1.75 |
Osteoporosis | 2.5 | 1.3 | 0.92 |
pancreatic cancer | 0.6 | 0.3 | 1 |
Parkinson's Disease | 8.2 | 7.5 | 0.09 |
Polycystic ovary syndrome | 6.3 | 3.1 | 1.03 |
Postural orthostatic tachycardia syndrome | 0.2 | 0.6 | -2 |
Premenstrual dysphoric disorder | 0.7 | 0.4 | 0.75 |
primary biliary cholangitis | 1.2 | 1.4 | -0.17 |
Primary sclerosing cholangitis | 2.6 | 2.6 | 0 |
Psoriasis | 3.6 | 2.8 | 0.29 |
rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 8.3 | 4 | 1.08 |
Rosacea | 1.2 | 1 | 0.2 |
Schizophrenia | 6.9 | 3.1 | 1.23 |
scoliosis | 0.9 | 1.2 | -0.33 |
Sjögren syndrome | 3.1 | 3.2 | -0.03 |
Sleep Apnea | 1.9 | 1.8 | 0.06 |
Slow gastric motility / Gastroparesis | 1.5 | 0.3 | 4 |
Small Intestinal Bacterial Overgrowth (SIBO) | 2 | 0.6 | 2.33 |
Stress / posttraumatic stress disorder | 2.9 | 2.7 | 0.07 |
Systemic Lupus Erythematosus | 4.2 | 2.3 | 0.83 |
Tic Disorder | 1.5 | 1.8 | -0.2 |
Tourette syndrome | 0.9 | 0.3 | 2 |
Type 1 Diabetes | 4.1 | 4.4 | -0.07 |
Type 2 Diabetes | 9 | 7.9 | 0.14 |
Ulcerative colitis | 6.5 | 6.8 | -0.05 |
Unhealthy Ageing | 5.6 | 2.4 | 1.33 |
Vitiligo | 2.1 | 1.5 | 0.4 |
Explanations /Info /Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction.
Copyright 2016 - 2025 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription All rights served. Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 Β§β―1030, CETS No.185, CFAA Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license. Caveat emptor: Analysis and suggestions are based on modelling(and thus infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models. Inventions /Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions,
or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not in strict compliance with Personal Health Information Laws. [216.73.216 ]